Tonix Pharmaceuticals (NASDAQ:TNXP) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research report released on Friday morning. The brokerage issued a sell rating on the stock.

Separately, Dawson James assumed coverage on Tonix Pharmaceuticals in a research note on Wednesday, February 28th. They issued a buy rating and a $3.00 price target for the company.

Tonix Pharmaceuticals Price Performance

Shares of NASDAQ:TNXP opened at $0.16 on Friday. Tonix Pharmaceuticals has a 1-year low of $0.12 and a 1-year high of $3.31. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.53 and a quick ratio of 1.81. The business has a 50-day moving average price of $0.29 and a two-hundred day moving average price of $0.39.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings data on Monday, April 1st. The company reported ($0.86) earnings per share for the quarter. The business had revenue of $3.78 million during the quarter, compared to analysts’ expectations of $3.95 million. On average, equities research analysts expect that Tonix Pharmaceuticals will post -3.71 earnings per share for the current year.

Institutional Trading of Tonix Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. increased its stake in shares of Tonix Pharmaceuticals by 12.3% in the 1st quarter. BlackRock Inc. now owns 34,392,362 shares of the company’s stock valued at $7,916,000 after acquiring an additional 3,760,804 shares during the last quarter. Renaissance Technologies LLC increased its stake in Tonix Pharmaceuticals by 79.4% during the 1st quarter. Renaissance Technologies LLC now owns 19,200,435 shares of the company’s stock worth $4,420,000 after purchasing an additional 8,500,604 shares in the last quarter. State Street Corp increased its stake in Tonix Pharmaceuticals by 11.4% during the 1st quarter. State Street Corp now owns 7,446,104 shares of the company’s stock worth $1,714,000 after purchasing an additional 764,518 shares in the last quarter. Northern Trust Corp increased its stake in Tonix Pharmaceuticals by 7.8% during the 1st quarter. Northern Trust Corp now owns 4,139,924 shares of the company’s stock worth $952,000 after purchasing an additional 300,199 shares in the last quarter. Finally, Armistice Capital LLC increased its stake in Tonix Pharmaceuticals by 160.0% during the 4th quarter. Armistice Capital LLC now owns 3,770,000 shares of the company’s stock worth $1,519,000 after purchasing an additional 2,320,000 shares in the last quarter. 82.26% of the stock is owned by institutional investors.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.